Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2015

Open Access 01-12-2015 | Review article

Quality of reporting randomized controlled trials (RCTs) in diabetes in Iran; a systematic review

Authors: Faeze Gohari, Hamid Reza Baradaran, Morteza Tabatabaee, Shabnam Anijidani, Fatemeh Mohammadpour Touserkani, Rasha Atlasi, Maryam Razmgir

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2015

Login to get access

Abstract

Objective

To determine the quality of randomized controlled clinical trial (RCT) reports in diabetes research in Iran.

Design

Systematized review.

Methods

We included RCTs conducted on diabetes mellitus in Iran. Animal studies, educational interventions, and non-randomized trials were excluded. We excluded duplicated publications reporting the same groups of participants and intervention. Two independent reviewers identify all eligible articles specifically designed data extraction form. We searched through international databases; Scopus, ProQuest, EBSCO, Science Direct, Web of Science, Cochrane Library, PubMed; and national databases (In Persian language) such as Magiran, Scientific Information Database (SID) and IranMedex from January 1995 to January of 2013 Two investigators assessed the quality of reporting by CONSORT 2010 (Consolidated Standards of Reporting Trials) checklist statemen.t,. Discrepancies were resolved by third reviewer consulting.

Results

One hundred and eight five (185) studies were included and appraised. Half of them (55.7 %) were published in Iranian journals. Most (89.7 %) were parallel RCTs, and being performed on type2 diabetic patients (77.8 %). Less than half of the CONSORT items (43.2 %) were reported in studies, totally. The reporting of randomization and blinding were poor. A few studies 15.1 % mentioned the method of random sequence generation and strategy of allocation concealment. And only 34.8 % of trials report how blinding was applied.

Conclusions

The findings of this study show that the quality of RCTs conducted in Iran in diabetes research seems suboptimal and the reporting is also incomplete however an increasing trend of improvement can be seen over time. Therefore, it is suggested Iranian researchers pay much more attention to design and methodological quality in conducting and reporting of diabetes RCTs.
Appendix
Available only for authorised users
Literature
2.
go back to reference Danaei G, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose), et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.CrossRefPubMed Danaei G, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose), et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.CrossRefPubMed
3.
go back to reference Dagenais GR, et al. Variations in diabetes prevalence in Low-, middle-, and high-income countries: results from the prospective urban and rural epidemiology study. Diabetes Care. 2016;10. Dagenais GR, et al. Variations in diabetes prevalence in Low-, middle-, and high-income countries: results from the prospective urban and rural epidemiology study. Diabetes Care. 2016;10.
4.
go back to reference Esteghamati A, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran national survey of risk factors for non-communicable diseases of Iran. Diabetes Care. 2008;31(1):96–8.CrossRefPubMed Esteghamati A, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran national survey of risk factors for non-communicable diseases of Iran. Diabetes Care. 2008;31(1):96–8.CrossRefPubMed
5.
go back to reference Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.CrossRefPubMedPubMedCentral Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.CrossRefPubMedPubMedCentral
6.
go back to reference Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–13.CrossRefPubMed Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–13.CrossRefPubMed
7.
go back to reference Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, Gotzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ. 2005;330(7499):1049–52.CrossRefPubMedPubMedCentral Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, Gotzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ. 2005;330(7499):1049–52.CrossRefPubMedPubMedCentral
8.
go back to reference Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276(8):637–9.CrossRefPubMed Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276(8):637–9.CrossRefPubMed
9.
go back to reference Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191–4.CrossRefPubMed Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191–4.CrossRefPubMed
10.
go back to reference Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332Azizi.CrossRef Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332Azizi.CrossRef
11.
go back to reference Altman DG, Moher D, Schulz KF. Improving the reporting of randomised trials: the CONSORT Statement and beyond. Stat Med. 2012;31(25):2985–97.CrossRefPubMed Altman DG, Moher D, Schulz KF. Improving the reporting of randomised trials: the CONSORT Statement and beyond. Stat Med. 2012;31(25):2985–97.CrossRefPubMed
12.
go back to reference Kilkenny C, et al. “Survey of the quality of experimental design, statistical analysis and reporting of research using animals.”. PloS one. 2009;4(11):e7824.CrossRefPubMedPubMedCentral Kilkenny C, et al. “Survey of the quality of experimental design, statistical analysis and reporting of research using animals.”. PloS one. 2009;4(11):e7824.CrossRefPubMedPubMedCentral
13.
Metadata
Title
Quality of reporting randomized controlled trials (RCTs) in diabetes in Iran; a systematic review
Authors
Faeze Gohari
Hamid Reza Baradaran
Morteza Tabatabaee
Shabnam Anijidani
Fatemeh Mohammadpour Touserkani
Rasha Atlasi
Maryam Razmgir
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2015
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-016-0258-2

Other articles of this Issue 1/2015

Journal of Diabetes & Metabolic Disorders 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.